Chronic wounds—diabetic foot ulcers, pressure injuries, vascular insufficiency ulcers—fail to close because cellular and molecular processes that normally drive healing are disrupted.
Chronic wounds—diabetic foot ulcers, pressure injuries, vascular insufficiency ulcers—fail to close because cellular and molecular processes that normally drive healing are disrupted. Inflammation persists unchecked, angiogenesis (new blood-vessel growth) stalls, and the wound remains stuck in an early inflammatory phase, never progressing to tissue remodelling and epithelial closure. Exosomes (nano-scale vesicles secreted by cells and carrying proteins, lipids, and genetic material) have emerged as particularly promising for wound therapy because they cross-link immune signalling with fibroblast activation and growth-factor delivery. Umbilical-cord-derived fibroblasts and placental MSCs contribute direct cellular replacement of damaged dermis and subcutaneous layers. The proposed mechanism combines immunomodulation (damping excessive inflammation), stimulation of local vascular growth, and restoration of extracellular matrix architecture.
| Indikative Kosten · Bulgarien (EU) | €3,000–€8,000 |
|---|---|
| Globale Marktkostenfalle | €5,000–€15,000 (dvcstem.com) |
| Wichtigste untersuchte Zelltypen | Exosomes, Fibroblasts from Wharton's Jelly, MSCs from Amniotic Membrane |
| Genehmigungsstatus | Experimentell |
| Registrierte Studien (ClinicalTrials.gov) | 59 · 7 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Chronic wound cell and exosome therapy has been subject to 59 completed trials, with 7 currently enrolling participants. Trials span diabetic foot ulcers (majority), pressure wounds, and mixed aetiology chronic wounds. Closure rates (percentage of wounds achieving full epithelial coverage) in treated cohorts typically range from 55–85% over 8–16 weeks, compared to reported historical control rates of 20–40% for advanced wounds. Exosome-based studies specifically show wound-area reduction averaging 45–70% at 12 weeks. Trial heterogeneity in wound selection, cell dose, and delivery (topical, intradermal injection, or fibrin-scaffold embedding) limits meta-analysis.
Depending on assessment, a Chronic Wounds & Ulcers protocol may draw on:
Exosome or cellular wound therapy costs €4,500–8,000 for a full treatment course (typically 2–4 applications spaced 2–4 weeks apart). Baseline imaging (photography, planimetry or 3D scanning), wound cleaning, and offtake samples add €800–1,500. Ongoing dressing costs (specialised antimicrobial or growth-factor-enriched dressings often used post-cell delivery) can reach €300–600 per week for 8–12 weeks, significantly extending total investment.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Chronic Wounds & Ulcers cost-by-country breakdown, or compare the best countries for Chronic Wounds & Ulcers →
Vor der Buchung prüfen: Sicherheit & Regulierung, das Erholungsklima, ob Sie geeignet sind, und welcher Zelltyp zu Chronic Wounds & Ulcers passt.
Vollständiges Chronische Wunden und Geschwüre FAQ → · Chronische Wunden und Geschwüre Kostenaufschlüsselung →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Bin ich geeignet? · Welcher Zelltyp? · Types of clinics & best countries · Kostenrechner
Medizinisch geprüft vom Redaktionsteam von StemCellAtlas zusammen mit the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) der Partnerklinik Stem Plus (Sofia), gemäß ISSCR-, FDA- und EMA-Leitlinien. Educational information, not medical advice; figures indicative.
GMP-zertifizierte regenerative Medizin mitten in der EU — ab 3.000–8.000 €, ein Bruchteil der US- oder Deutschland-Preise. Individuelle Protokolle für internationale Patienten aus über 50 Ländern.
Kostenlose ärztliche Prüfung